Company patents
SANOFI BIOTECHNOLOGY
SANOFI BIOTECHNOLOGY's patent strategy is heavily concentrated in core pharma_biotech areas, with 100.0% of its portfolio in Peptides & Proteins and 83.6% in Pharmaceutical Preparations. While these core areas saw a rebound in 2025 (e.g., Pharmaceutical Preparations grew +62.5% YoY), it's surprising to see a significant decline in Therapeutic Activity (Pharma) patents so far in 2026, dropping -70.0% YoY, suggesting a potential shift in focus within its therapeutic development.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
55 US filings (since 2023) · 8 categories · 8 themes
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Patents
Showing 1-10 of 86